This means your blood has too little phosphate, a mineral important for bones, teeth, and energy. It can cause bone problems and other health issues.
Every report comes from a Lived member, sent anonymously.
Have you tried Enzyme Replacement Therapy for Hypophosphatasia?
Hypophosphatasia (HPP) is a rare inherited condition that weakens bones and teeth. It happens when the body makes too little working alkaline phosphatase, an enzyme that helps calcium and phosphate settle into bone and teeth so they become hard. Without enough of it, bones can stay soft and break easily, and teeth may loosen and fall out early. HPP varies more than most conditions. The most severe forms appear before birth or in the first months of life, with soft, poorly formed bones, a small chest that makes breathing difficult, and sometimes seizures. Children with milder forms may lose baby teeth early, walk late, have bowed legs or bone pain, or grow slowly. Adults may have repeated stress fractures in the feet or thigh, long-lasting muscle and bone pain, weakness, or early loss of adult teeth. The mildest form affects only the teeth. Despite the similar name, HPP is not the same as low blood phosphate (hypophosphatemia). The problem is a shortage of the enzyme, and blood phosphate levels are often normal or even high.
HPP is caused by changes (variants) in a single gene, ALPL, which carries the instructions for making alkaline phosphatase. When the enzyme works poorly, a natural substance called pyrophosphate builds up, and it blocks minerals from being deposited in bones and teeth. Variants that almost eliminate the enzyme's activity tend to cause the severe early forms, while variants that only reduce it usually cause milder disease. The severe forms that appear early in life are usually inherited from two parents who each carry one altered copy of the gene and have no symptoms themselves (autosomal recessive inheritance). Milder forms can follow that pattern or can come from a single altered copy passed down by one parent (autosomal dominant inheritance), so relatives can be affected to very different degrees. Severe forms affect roughly 1 in 100,000 newborns. Milder forms are probably more common and often go unrecognized.
The central clue is a persistently low level of alkaline phosphatase (ALP) on a routine blood test. Low ALP results are often overlooked, and they must be judged against the normal range for the person's age and sex: children normally have much higher ALP than adults, so a child's result can be abnormally low while still looking normal by adult standards. One low result is not enough on its own, because severe illness, recent surgery or injury, and low zinc or magnesium can also lower ALP. When HPP is suspected, clinicians look for a buildup of substances the enzyme normally breaks down. A raised blood level of pyridoxal 5'-phosphate (PLP, the active form of vitamin B6) is a common supporting test, and vitamin B6 (pyridoxine) supplements should be stopped for at least a week beforehand so they do not skew the result. Genetic testing for ALPL variants can confirm the diagnosis. X-rays may show rickets in children or pseudofractures (incomplete cracks, often in the thigh bone) in adults, and severe forms can be seen on a prenatal ultrasound. Because bone pain, fatigue and fractures overlap with more common conditions, HPP is often diagnosed late; one review estimated a median of almost six years after the first symptoms. In adults it is sometimes mistaken for osteoporosis or fibromyalgia.
Treatment depends on age and severity, and is usually coordinated by a team that may include a metabolic bone specialist or endocrinologist, a dentist, a physical therapist and an orthopedic surgeon. Asfotase alfa (Strensiq) is an enzyme replacement therapy: a lab-made version of the missing enzyme, designed to travel to bone and do its job there. It is injected under the skin several times a week, usually long term. In infants and children with severe HPP it has markedly improved survival, helped rickets heal, and improved breathing, growth and movement. In the US it is approved for HPP that began in infancy or childhood, including in adults whose disease started young, but not for HPP that first appears in adulthood. In adults it has helped pseudofractures heal, but responses vary and it may not fully relieve pain, fatigue or weakness. The trade-offs are frequent injections, common redness, swelling or itching where the shot is given, changes in the fat under the skin at repeated injection sites, and rare but serious allergic reactions, which is why treatment starts under medical supervision. People taking it have eye exams and kidney ultrasounds at the start and from time to time afterward to check for calcium deposits. Supportive care matters at every stage. Anti-inflammatory pain relievers (NSAIDs such as ibuprofen or naproxen) are commonly used for bone and joint pain, while opioids are of limited use. Physical therapy and tailored exercise help build and keep strength, ideally avoiding the kind of overexertion that can bring on prolonged pain. Orthotics (supportive shoe inserts or braces) can help, and surgery may be needed to correct deformities or to stabilize fractures, often with a rod placed inside the bone. Infants with seizures caused by HPP are treated with vitamin B6. Vitamin D follows the same guidance as for anyone else, and calcium supplements are not a treatment for HPP; infants with high blood calcium may actually need less calcium. Regular dental care helps protect teeth. One caution stands out. Bisphosphonates, the common osteoporosis medicines such as alendronate (Fosamax), are considered unsafe in HPP. They resemble the substance that already builds up, and they can worsen bone softening and raise the risk of unusual thigh fractures. Similar concerns apply to denosumab (Prolia), another osteoporosis medicine. This is one reason adults with fractures and an unexplained low ALP should be checked for HPP before osteoporosis treatment begins.
The outlook depends heavily on the form. Before enzyme replacement was available, more than half of newborns with the most severe form died, mostly from breathing failure. With early treatment many now survive, though they need close specialist follow-up through childhood. Children with milder forms may need support with walking, growth and dental care. Some are monitored for craniosynostosis, in which the skull bones join too early and can raise pressure on the brain. This is checked with regular exams, eye examinations and imaging, and sometimes needs surgery. Adults commonly live with chronic pain, fatigue, muscle weakness and fractures that heal slowly, which can affect work, exercise and everyday activity. Pacing exercise, managing pain and planning any bone surgery with clinicians who know HPP are the main ways to protect function. Follow-up typically includes dental care, blood tests of minerals such as calcium and phosphate (especially in infants), kidney checks, and attention to any new pain that could signal a stress fracture. Because HPP is inherited, a diagnosis in one person can matter for relatives. Genetic counseling can help a family understand the chance of passing it on and whether others should be tested.
Ask about testing for HPP if a child loses baby teeth early with the roots still attached, walks late or has unexplained bone pain, or if an adult has repeated foot stress fractures, thigh pseudofractures, fractures that heal slowly, or a low ALP result that was never explained. If you have HPP, tell any clinician who suggests an osteoporosis medicine. Contact the care team promptly about new or worsening pain in the thigh, hip or foot, which can signal a developing fracture, or a change in a child's head shape. An infant with HPP who has trouble breathing or a seizure needs emergency care. For anyone receiving asfotase alfa, trouble breathing, a choking feeling, swelling around the eyes or dizziness soon after an injection can be a severe allergic reaction: call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
How old were you when diagnosed with HPP?